Investigating the effect of independent, blinded digital image assessment on the STOP GAP trial.

Background: Blinding is the process of keeping treatment assignment hidden and is used to minimise the possibility of bias. Trials at high risk of bias have been shown to report larger treatment effects than low-risk studies. In dermatology, one popular method of blinding is to have independent outc...

Descripción completa

Detalles Bibliográficos
Publicado en:Trials Vol. 18; pp. 1 - 11
Autores principales: Patsko, Emily, Godolphin, Peter J., Thomas, Kim S., Hepburn, Trish, Mitchell, Eleanor J., Craig, Fiona E., Bath, Philip M., Montgomery, Alan A.
Formato: research randomized controlled trial Journal Article
Publicado: BioMed Central 2/2/2017
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=122975554&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 122975554
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        17456215
        38OC
      jtl: Trials
      issn: 17456215
      maglogo: N
    pubinfo:
      dt: 2/2/2017
      vid: 18
      pid: 24147
      pub: BioMed Central
    artinfo:
      ui:
        122975554
        122975554
        NLM28153051
        122975554
        10.1186/s13063-017-1779-9
        NLM28153051
        122975554
      ppf: 1
      ppct: 10
      formats:
      tig:
        atl: Investigating the effect of independent, blinded digital image assessment on the STOP GAP trial.
      aug:
        au:
          Patsko, Emily
          Godolphin, Peter J.
          Thomas, Kim S.
          Hepburn, Trish
          Mitchell, Eleanor J.
          Craig, Fiona E.
          Bath, Philip M.
          Montgomery, Alan A.
        affil: Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK
      sug:
        subj:
          Pyoderma Gangrenosum Drug Therapy
          Skin Drug Effects
          Prednisolone Therapeutic Use
          Immunosuppressive Agents Therapeutic Use
          Photography Methods
          Cyclosporine Therapeutic Use
          Image Interpretation, Computer Assisted
          Pyoderma Gangrenosum Pathology
          Aged
          Cyclosporine Adverse Effects
          Software
          Time Factors
          Wound Healing Drug Effects
          Male
          Female
          Prednisolone Adverse Effects
          Human
          Middle Age
          Reproducibility of Results
          Judgment
          Skin Pathology
          Adult
          Immunosuppressive Agents Adverse Effects
          Predictive Value of Tests
          Observer Bias
          Study Design
          Treatment Outcomes
          Comparative Studies
          Multicenter Studies
          Randomized Controlled Trials
          Evaluation Research
          Validation Studies
          Scales
          Ways of Coping Questionnaire
          Aged: 65+ years
          Middle Aged: 45-64 years
          Adult: 19-44 years
          Male
          Female
      ab: Background: Blinding is the process of keeping treatment assignment hidden and is used to minimise the possibility of bias. Trials at high risk of bias have been shown to report larger treatment effects than low-risk studies. In dermatology, one popular method of blinding is to have independent outcome assessors who are unaware of treatment allocation assessing the endpoint using digital photographs. However, this can be complex, expensive and time-consuming. The objective of this study was to compare the effect of blinded and unblinded outcome assessment on the results of the STOP GAP trial.Methods: The STOP GAP trial compared prednisolone to ciclosporin in treating pyoderma gangrenosum. Participants' lesions were measured at baseline and at 6 weeks to calculate the primary outcome, speed of healing. Independent blinded assessors obtained measurements from digital photographs using specialist software. In addition, unblinded treating clinicians estimated lesion area by measuring length and width. The primary outcome was determined using blinded measurements where available, otherwise unblinded measurements were used (method referred to as trial measurements). In this study, agreement between the trial and unblinded measurements was determined using the intraclass correlation coefficient (ICC). The STOP GAP trial's primary analysis was repeated using unblinded measurements only. We introduced differential and nondifferential error in unblinded measurements and investigated the effect on the STOP GAP trial's primary analysis.Results: Eighty-six (80%) of the 108 patients were assessed using digital images. Agreement between trial and unblinded measurements was excellent (ICC = 0.92 at baseline; 0.83 at 6 weeks). There was no evidence that the results of the trial primary analysis differed according to how the primary outcome was assessed (p value for homogeneity = 1.00).Conclusions: Blinded digital image assessment in the STOP GAP trial did not meaningfully alter trial conclusions compared with unblinded assessment. However, as the process brought added accuracy and credibility to the trial it was considered worthwhile. These findings question the usefulness of digital image assessment in a trial with an objective outcome and where bias is not expected to be excessive. Further research should investigate if there are alternative, less complex ways of incorporating blinding in clinical trials.Trial Registration: Current Controlled Trials, www.isrctn.com ISRCTN35898459. Registered on 26 May 2009.
      pubtype: Academic Journal
      doctype:
        research
        randomized controlled trial
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N